

SENTARA HEALTH PLANS

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-844-668-1550**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is not complete, correct, or legible, authorization can be delayed.**

For Medicare Members: Medicare Coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Drug Requested: Nucala[®] SQ (mepolizumab) (J2182) (Medical)
{Hypereosinophilic Syndrome (HES)}

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Weight: _____ Date: _____

Recommended Dosage: 300 mg/mL SubQ once every 4 weeks administered as 3 separate 100-mg injections

Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

*The Health Plan considers the use of concomitant therapy with Cinqair[®], Dupixent[®], Fasenra[®], Nucala[®], Tezspire[®] and Xolair[®] to be experimental and investigational. Safety and efficacy of these combinations have NOT been established and will NOT be permitted. In the event a member has an active Cinqair[®], Dupixent[®], Fasenra[®], Tezspire[®] or Xolair[®] authorization on file, all subsequent requests for Nucala[®] will NOT be approved.

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial Authorization: 12 months

- Member is \geq 12 years of age
- Prescriber is or has consulted with an Allergist, Immunologist, Pulmonologist or Rheumatologist
- Member has a diagnosis of HES for 6 months or longer without any non-hematologic secondary cause (i.e. drug hypersensitivity, parasitic helminth infection, human immunodeficiency virus infection, non-hematologic malignancy) (**submit chart notes and labs confirming diagnosis**)
- Member has FIP1L1-PDGFR α -negative disease
- Member has had two or more episodes of HES-related flares (worsening of clinical symptoms and/or worsening of blood eosinophil counts) requiring escalation of therapy in the past 12 months (**submit chart notes**)
- Member's HES-related flares occur spontaneously and did **NOT** occur within 4 weeks of a decrease in therapy
- Member has been on a stable dose of HES therapy (such as oral corticosteroids, immunosuppressive agents and/or cytotoxic therapy) for the past 4 or more weeks (**verified by chart notes and/or pharmacy paid claims**)
- Member's blood eosinophil count is \geq 1000 cells/microliter while taking stable doses of HES therapy (**submit labs obtained within 4 weeks of request**)

Reauthorization: 12 months. All criteria must be checked for approval. To support each line checked, all documentation (lab results, diagnostics, and/or chart notes) must be provided or request may be denied.

- Member has experienced a positive response to Nucala[®] therapy as determined by the prescriber (i.e. decreased number of flares, improved fatigue, reduced corticosteroid requirements, and decreased eosinophil levels) (**submit chart notes**)

Medication being provided by a Specialty Pharmacy – Proprium Rx

For urgent reviews: Practitioner should call Sentara Health Plans Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health Plan's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****